1. Scrip
  2. >>Business
  3. >>Deals

Redx Cashes In Cancer Program With Jazz Pact

 
• By Kevin Grogan

Shares in the UK biotech tripled to a 52-week high after it announced the sale of its pan-RAF inhibitor program to Jazz that could eventually be worth around $200m.

Balance sheet
THE JAZZ CASH will HELP redx balance the books this year • Source: Shutterstock

Redx Pharma PLC has seen its valuation more than double after selling off another preclinical asset with Jazz Pharmaceuticals PLC getting its hands on the UK firm's pan-RAF inhibitor program.

As part of the agreement, Redx will receive an upfront fee of $3.5m in cash but is eligible to receive...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Deal Watch: XOMA Buys Troubled Alkermes-Spinout Mural Oncology

 
• By Joseph Haas, Xu Hu, and Lisa Takagi

Plus deals involving Fosun/Accro, Fosun/Sitala, RemeGen/Santen, Firebird/Solasia and more, including tech transfer.

Novo Adds Another Prong To Its RNA Ambitions With Replicate Deal

 
• By Jessica Merrill

Replicate is a clinical-stage company developing a next-generation self-replicating RNA technology. CEO Nathanial Wang talked to Scrip about the deal.

Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals

 
• By Andrew McConaghie

Superluminal’s CEO Cony D’Cruz believes its focus on GPCRs has already yielded a best-in-class obesity candidate for its own pipeline, as well as its $1bn- plus deal with Eli Lilly.

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 
• By Sushmita Panda

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

More from Business

MannKind Snaps Up scPharmaceuticals In Cardiorenal Expansion

 
• By Sushmita Panda

The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.

Nippon Kayaku Aims To Broaden Portfolio Via Singaporean JV

 
• By Lisa Takagi

Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.

A Decade Of Transformation: Dong-A ST Readies For Take Off As An Innovative Pharma

 
• By Jung Won Shin

Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.